Litcius/Paper detail

Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

Kristian Reich, Jacob P. Thyssen, Andrew Blauvelt, Kilian Eyerich, Weily Soong, Zakiya P. Rice, Hwanhee Hong, Norito Katoh, Fernando Valenzuela, Marco DiBonaventura, Tamara A. Bratt, Fan Zhang, Claire Clibborn, Ricardo Rojo, Hernán Valdez, Urs Kerkmann

2022The Lancet238 citationsDOI

Topics & Concepts

DupilumabAtopic dermatitisMedicineDouble blindDermatologyRandomized controlled trialInternal medicineAlternative medicinePlaceboPathologyDermatology and Skin DiseasesPsoriasis: Treatment and PathogenesisDrug-Induced Adverse Reactions